Zacks Small Cap Research on MSN
APVO: Initiating coverage of Aptevo Therapeutics Inc.; unlocking the next generation of multispecific immune engagement
By David Bautz, PhD NASDAQ: APVO READ THE FULL APVO RESEARCH REPORT We are initiating coverage of Aptevo Therapeutics Inc. (NASDAQ: APVO) with a valuation of $30.00. Aptevo is a clinical-stage ...
Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...
Conclusion: ATG-207 represents a differentiated immune tolerance–restoring strategy that integrates precision T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results